Get the Stockscreener App
6.645
4.58%
0.275
Arcturus Therapeutics Holdings Inc stock is traded at $6.645, with a volume of 329.39K.
It is up +4.58% in the last 24 hours and down -6.57% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$6.37
Open:
$6.26
24h Volume:
329.39K
Relative Volume:
0.27
Market Cap:
$189.24M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-5.7284
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
+7.62%
1M Performance:
-6.57%
6M Performance:
-51.66%
1Y Performance:
-65.07%
1-Day Range:
$6.26
$6.69
1-Week Range:
$6.015
$6.69
52-Week Range:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.66 | 181.00M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - marketscreener.com
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
Arcturus Therapeutics Holdings files for mixed shelf of up to $500 millionSEC filing - marketscreener.com
Arcturus Therapeutics Files $500 Million Mixed Shelf - marketscreener.com
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics (ARCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will Arcturus Therapeutics Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & Risk Controlled Daily Trade Plans - Улправда
How strong is Arcturus Therapeutics Holdings Inc. stock balance sheetMarket Activity Report & Weekly Watchlist of Top Performers - Улправда
How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataTrade Risk Assessment & Weekly High Return Stock Forecasts - Улправда
Why Arcturus Therapeutics Holdings Inc. stock could outperform in 2025Weekly Market Report & Daily Momentum Trading Reports - DonanımHaber
How supply chain issues affect Arcturus Therapeutics Holdings Inc. stockWeekly Trend Recap & AI Enhanced Market Trend Forecasts - DonanımHaber
Arcturus Therapeutics Holdings Inc. Announces Management Changes - marketscreener.com
Arcturus Therapeutics CFO Andy Sassine to leave company - marketscreener.com
Arcturus Therapeutics announces CFO transition and interim appointment By Investing.com - Investing.com Australia
Arcturus Therapeutics Announces CFO Departure and Replacement - TipRanks
Arcturus Therapeutics announces CFO departure and replacement - MSN
Arcturus Therapeutics announces CFO transition and interim appointment - Investing.com
Arcturus Therapeutics Announces CFO Departure and Interim Appointment - TradingView — Track All Markets
Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Institution Moves: How buyback programs support Comerica Incorporated Depositary Shares each stockJuly 2025 Spike Watch & Daily Technical Stock Forecast Reports - moha.gov.vn
Retail Surge: How interest rate cuts could boost Arcturus Therapeutics Holdings Inc stock 1; waitfor delay '0:0:15' - moha.gov.vn
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know - MSN
Can Arcturus Therapeutics Holdings Inc. stock hit analyst price targetsJuly 2025 Outlook & Weekly Top Gainers Alerts - Newser
How Arcturus Therapeutics Holdings Inc. stock trades before earningsJuly 2025 Recap & AI Powered Buy and Sell Recommendations - Newser
(ARCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Guidance Update: How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataNew Guidance & Safe Entry Momentum Stock Tips - moha.gov.vn
Wells Fargo Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation - MSN
Will Arcturus Therapeutics Holdings Inc. stock deliver shareholder valueJobs Report & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Form 8-KCurrent report - ADVFN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - MarketScreener
Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline - Markets Mojo
Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles - Markets Mojo
Responsive Playbooks and the ARCT Inflection - Stock Traders Daily
What drives Arcturus Therapeutics Holdings Inc stock priceLow Beta Stocks & Free Trend Following Techniques - earlytimes.in
Is Arcturus Therapeutics Holdings Inc. stock a safe haven assetJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Balyasny Asset Management L.P. Increases Stake in Arcturus Thera - GuruFocus
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
What candlestick patterns are forming on Arcturus Therapeutics Holdings Inc. - newser.com
Can Arcturus Therapeutics Holdings Inc. stock beat market expectations this quarterJuly 2025 Analyst Calls & Fast Entry High Yield Tips - newser.com
Can momentum traders help lift Arcturus Therapeutics Holdings Inc.2025 Performance Recap & Detailed Earnings Play Strategies - newser.com
How Arcturus Therapeutics Holdings Inc. stock responds to policy changesNew Guidance & AI Powered Market Trend Analysis - newser.com
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):